Terminology Service for NFDI4Health
JSON

Ramucirumab

Go to external page http://purl.obolibrary.org/obo/NCIT_C70792

A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells. [ ]

Term info

Label

Ramucirumab

Synonyms
  • Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
  • Cyramza
  • IMC-1121B
  • LY3009806
  • Monoclonal Antibody HGS-ETR2
  • RAMUCIRUMAB
  • Ramucirumab
  • anti-VEGFR-2 fully human monoclonal antibody IMC-1121B
  • ramucirumab
Subsets

NCIT_C116978, NCIT_C63923, NCIT_C128784, NCIT_C157711, NCIT_C116977, NCIT_C157712

ALT DEFINITION

A substance being studied in the treatment of breast cancer that has come back. It binds to receptors for a protein called vascular endothelial growth factor (VEGF). This keeps VEGF from binding to the receptors and may stop the growth of new blood vessels that tumors need to grow. It is a type of antiangiogenesis agent and a type of monoclonal antibody.

Accepted Therapeutic Use For

multicentric Castleman's disease (MCD), metastatic colorectal cancer (mCRC); advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma; hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of >= 400 ng/mL

CAS Registry

947687-13-0

Display Name

Ramucirumab

FDA UNII Code

D99YVK4L0X

Has Target

http://purl.obolibrary.org/obo/NCIT_C28496

Legacy Concept Name

Anti-VEGFR-2_Fully_Human_Monoclonal_Antibody_IMC-1121B

Preferred Name

Ramucirumab

Semantic Type

Amino Acid, Peptide, or Protein, Immunologic Factor

UMLS CUI

C2742502

code

C70792